4 Analysts Have This To Say About Personalis
Personalis (NASDAQ:PSNL) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.Summarizing their recent assessments, the table below illustra
Tivic Health, RAPT Therapeutics, Notable Labs Among Healthcare Movers
Personalis (PSNL) Receives a Buy From Lake Street
Express News | Personalis Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Issued Q2 Revenue Guidance Above Estimates
Is Personalis (NASDAQ:PSNL) In A Good Position To Deliver On Growth Plans?
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Revolution Medicines (RVMD) and Personalis (PSNL)
Personalis Price Target Maintained With a $3.50/Share by Needham
Personalis Price Target Maintained With a $3.50/Share by Needham
Express News | Needham Reiterates Buy on Personalis, Maintains $3.5 Price Target
Personalis Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 105.88% Needham → $3.5 Reiterates Buy → Buy 04/30/2024 135.29% Lake Street → $4 Initiates Cover
Buy Rating Affirmed for Personalis Amid Strong Financial Performance and Strategic Growth Prospects
Personalis Inc (PSNL) (Q1 2024) Earnings Call Transcript Highlights: Surpassing Revenue ...
Express News | Personalis Sees Q2 Revenue $19.5M-$20.5M Vs $18.41M Est
Personalis Sees Q2 Revenue $19.5M-$20.5M Vs $18.41M Est.
Personalis Sees Q2 Revenue $19.5M-$20.5M Vs $18.41M Est.
Express News | Personalis Inc: Sees Q2 Total Company Revenue in Range of $19.5 Mln to $20.5 Mln
Express News | Personalis Inc: Sees Full Year Total Company Revenue of $76.0 Mln to $78.0 Mln
Personalis | 10-Q: Quarterly report
Personalis Q1 2024 GAAP EPS $(0.26) Beats $(0.38) Estimate, Sales $19.525M Beat $18.358M Estimate
Personalis (NASDAQ:PSNL) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.38) by 31.58 percent. This is a 57.38 percent increase over losses of $(0.61) p
Personalis Sees 2024 Revenue From Pharma Tests, Enterprise Sales, and All Other Customers in the Range of $68M-$70M >PSNL
Personalis Sees 2024 Revenue From Pharma Tests, Enterprise Sales, and All Other Customers in the Range of $68M-$70M >PSNL
Personalis Sees 2Q Rev $19.5M-$20.5M >PSNL
Personalis Sees 2Q Rev $19.5M-$20.5M >PSNL
Personalis Raises 2024 View To Rev $76M-$78M >PSNL
Personalis Raises 2024 View To Rev $76M-$78M >PSNL
No Data